NasdaqCM:FENCBiotechs
Fennec Pharmaceuticals (FENC) Quarterly Loss Near Breakeven Challenges Bearish Profitability Narratives
Fennec Pharmaceuticals (FENC) just posted its FY 2025 third quarter numbers, with revenue of US$12.5 million and a basic EPS loss of US$0.02, while net income excluding extra items came in at a loss of US$0.6 million. Over recent quarters the company has seen revenue move from US$7.3 million in Q2 FY 2024 to US$9.7 million in Q2 FY 2025 and then to US$12.5 million in Q3 FY 2025. Over the same period, basic EPS shifted from a loss of US$0.20 in Q2 FY 2024 to a loss of US$0.11 in Q2 FY 2025 and...